GlaxoSmithKline Gets FDA Priority Review of Belantamab Mafodotin in Multiple Myeloma

Date : 01/21/2020 @ 3:53PM
Source : Dow Jones News
Stock : GlaxoSmithKline PLC (GSK)
Quote : 38.08  0.55 (1.47%) @ 1:00AM
After Hours
Last Trade
Last $ 37.90 ▼ -0.18 (-0.47%)

GlaxoSmithKline Gets FDA Priority Review of Belantamab Mafodotin in Multiple Myeloma

GlaxoSmithKline (NYSE:GSK)
Historical Stock Chart

3 Months : From Jan 2020 to Apr 2020

Click Here for more GlaxoSmithKline Charts.

By Colin Kellaher


GlaxoSmithKline PLC (GSK.LN, GSK) on Tuesday said the U.S. Food and Drug Administration granted priority review to its biologics license application for belantamab mafodotin in a form of the blood cancer multiple myeloma.

The U.K. drug maker said the application covers the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.


Write to Colin Kellaher at


(END) Dow Jones Newswires

January 21, 2020 10:38 ET (15:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest GSK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.